Gilead stops last PhIII of CD47 drug, citing FDA hold, higher risk of death in treatment arm

Gilead discontinued its remaining Phase III study of magrolimab, an anti-CD47 antibody that the company was testing for acute myeloid leukemia and its precursor disease, and it will not pursue future work on this therapy in blood cancers.

In an interim analysis, patients who received magrolimab had an increased risk…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks